Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.
Lilly’s bid to acquire Scorpion was driven by the Scorpion’s PI3Kα inhibitor program that is centered on the drug STX-478. The drug is in clinical studies evaluating its potential in solid tumours and ...
Potential antitrust deregulation could foster a more favourable environment for larger M&A deals, though skepticism remains.
Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according ...
NEW YORK – Eli Lilly on Monday said it will acquire Scorpion Therapeutics' mutant-PI3Kα inhibitor STX-478 for up to $2.5 billion while Scorpion spins out a new entity to develop its non-PI3Kα assets.
The company will acquire Scorpion's experimental oral therapy, STX-478, which is currently being tested in early-stage trials ...
Pharmaceutical giant Eli Lilly & Co. (LLY) is buying privately held Scorpion Therapeutics’ experimental cancer therapy for $2 ...
US pharma major Eli Lilly is to buy the PI3Kα inhibitor program STX-478 from Scorpion Therapeutics, a private US biotech ...
Indianapolis: Eli Lilly and Company and Scorpion Therapeutics, Inc., a private biotechnology company developing small ...
Eli Lilly and Co. announced Monday that it is buying Boston-based Scorpion Therapeutics and its targeted breast cancer ...
Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ("Scorpion"), a private biotechnology company developing small molecule precision oncology therapies, today announced a definitive ...
Lilly will acquire Scorpion's experimental oral therapy, STX-478, which is currently being tested in early-stage trials for breast cancer and other advanced solid tumors. As part of the deal, Scorpion ...